Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

5 takeaways from the latest White House Coronavirus Task Force meeting

By Brian Buntz | November 20, 2020

coronavirus

[Coronavirus image courtesy of World Health Organization]

The White House Coronavirus Task Force promised a swift rollout of COVID-19 vaccines — but one of a number of takeaways from its first briefing since July.

The briefing yesterday gave the task force a chance to once again urge Americans to heed COVID-19 guidance while also providing an update on vaccines and therapeutics.  

The Task Force came as the U.S. is battling an unprecedented surge in COVID-19 cases. Deaths from the virus recently surpassed 250,000. For the sake of comparison, the flu kills roughly 42,000 each year, according to the Centers for Disease Control and Prevention (CDC).

1. Distribution of COVID-19 vaccines will be ‘virtually immediate’

The White House Coronavirus Task Force has long promised a swift rollout of COVID-19 vaccines after they win emergency use authorization from the FDA. 

Following an FDA decision to grant a vaccine candidate Emergency Use Authorization, vaccine distribution will occur swiftly. “We have a system in place to begin within 24 hours, shipping that vaccine to hospitals, healthcare facilities, and 24 hours after that, literally injecting that vaccine into Americans,” said Vice President Mike Pence.  

2. Two COVID-19 vaccine candidates could be almost as effective as the measle vaccine

FDA initially required that COVID-19 vaccines be at least 50% effective. But data from Phase 3 trials suggest that the Pfizer and Moderna vaccines are about 95% efficacious. “For those of you not acquainted with the field of vaccinology, that is extraordinary,” said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. “That is almost to the level of what we see with [the] measles [vaccine], which is 98% effective.”  

3. Fauci spoke up against fight vaccine hesitancy

Vaccine hesitancy was a problem before the COVID-19 pandemic, but the significant public mistrust of vaccines endangers thousands of lives in the U.S. 

There has been “some reticence of people,” Fauci said. A segment of the public is concerned that vaccine development had been rushed. “The process [of developing vaccines at record speed] did not compromise at all, safety, nor did it compromise scientific integrity,” Fauci said. “It was a reflection of the extraordinary scientific advances in these types of vaccines, which allowed us to do things in months that actually took years before.”   

Fauci also stressed that independent data and safety monitoring boards have reviewed COVID-19 clinical trials. He also highlighted the role of the independent Vaccines and Related Biological Products Advisory Committee as an FDA advisor for COVID-19-related vaccine decisions. 

4. The plan to distribute vaccines will rely heavily on private enterprise

As Vice President Pence said during the briefing, the White House Coronavirus Task Force is using a “federally supported state-managed and locally executed” strategy to fight the pandemic. But when it comes to distributing the vaccine, the plan uses a public-private partnership that draws on the capabilities of private enterprise as well as federal organizations such as CDC. 

“We knew if we brought Pfizer, Moderna, McKesson, UPS, FedEx, CVS, Walgreens and hundreds of others together that we would come up with the best solutions,” said General Gustave F. Perna, chief operating officer of Operation Warp Speed. 

The task force started by looking at facilities where the public would most likely feel comfortable receiving vaccines — drug stores, doctors’ offices and other healthcare facilities — and worked backward up the supply chain to streamline distribution. “We take the Pfizer vaccine. They are capable of distributing on their own,” Perna said. “They will utilize FedEx and UPS in order to execute distribution.”

Simultaneously, the Department of Health and Human Services will coordinate the shipment of vaccine supply kits, including syringes, alcohol wipes and other supplies needed to administer vaccines. The government has a stockpile of 100 million of such kits.  

For the Moderna vaccine, the government plans to sync vaccine and ancillary kit shipments at a distribution warehouse. “We are going to put them together, and then we’re going to distribute through FedEx and UPS down to our administration sites,” Perna said. 

“We can distribute the Pfizer vaccine at a minimum of 975 doses, and the Moderna vaccine at a minimum of 100 doses,” he added. 

5. The task force also highlighted antibody drugs

While the White House Coronavirus Task Force has underscored the importance of a vaccine since its inception, the recent briefing also highlighted antibody-based drugs. “Last week, we approved Eli Lilly’s monoclonal antibody,” said Secretary of Health and Human Services Alex Azar. “We shipped product that very afternoon to patients,” he added. Already, Lilly has shipped 60,000 courses of therapy to healthcare facilities across the U.S. “And Regeneron’s combination monoclonal antibody is pending at the FDA right now,” Azar said.  

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].

Tell Us What You Think! Cancel reply

Related Articles Read More >

Rendering of Eli Lilly facility in Lehigh Valley, PA (1)
Lilly to build $3.5B injectable medicine, device manufacturing plant in Pennsylvania
Cellares Logo (1)
Cellares raises $257M to industrialize cell therapy manufacturing
Antheia_Logo (1)
Antheia closes $80M financing to strengthen U.S. drug manufacturing
This is the logo of Johnson & Johnson.
Johnson & Johnson announces new North Carolina pharma plant
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE